Dynatronics (DYNTQ) AI Stock Analysis

• Market Cap: $107.53K
• Dividend Yield: N/A
• Average Volume (3M): 9.46K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.70
• Revenue Growth: -12.89%
• EPS Growth: -64.68%
• Country: US
• Employees: 111
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): N/A
• Shares Outstanding: 16,048,735
• 10 Day Avg. Volume: 9,367
• 30 Day Avg. Volume: 9,464
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.21
• Price to Sales (P/S): 0.02
• P/FCF Ratio: 2.48
• Enterprise Value/Market Cap: 58.11
• Enterprise Value/Revenue: 0.23
• Enterprise Value/Gross Profit: 1.08
• Enterprise Value/Ebitda: -0.67
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 40 Underperform
• Price Target: $0.01 ▼(-75.00% Downside)
• Action: Reiterated Date: 01/28/26
• Date: Action: Reiterated 01/28/26

The score is driven primarily by weak financial performance (declining revenue, ongoing losses, high leverage, and strained cash flow). Technical indicators reinforce the risk with a pronounced downtrend and very weak momentum. Valuation does not offset these concerns because the negative P/E is not informative and there is no dividend yield support.

Positive Factors

Recurring consumables revenue

Dynatronics' sales mix includes consumables and accessories that generate repeat purchases tied to installed devices. This creates a durable aftermarket revenue stream and predictable recurring demand that can partially offset equipment sales cyclicality and support margin resilience over months.

Broad therapeutic product portfolio

A diversified product set across multiple therapeutic modalities reduces single-product concentration risk, enables cross-selling to clinics and rehab providers, and leverages manufacturing/distribution capabilities to sustain revenue channels and customer relationships over medium-term industry cycles.

Positive FCF-to-net-income conversion metric

A positive free cash flow to net income ratio indicates the company can convert earnings into cash when profitability recovers. That structural cash-conversion potential supports future deleveraging or reinvestment if margins improve, providing a pathway to stronger financial health over several quarters.

Negative Factors

Declining revenue and negative margins

Sustained revenue declines and negative operating and net margins erode scale economics and limit resources for R&D, sales, and service. Over months this constrains ability to stabilize margins, hampers reinvestment in the installed base, and increases reliance on outside financing.

High leverage

A debt-to-equity ratio above 2 indicates significant leverage that raises interest burden and refinancing risk. For a loss-making medical-device firm this reduces financial flexibility to fund operations, invest in product support, or ride out demand variability over the medium term.

Weak cash generation and liquidity pressure

Negative FCF growth and weak operating cash coverage signal ongoing liquidity strain. This limits working-capital resilience, may force dilutive financing or cost cutting, and undermines the company's ability to sustain supply, service, and aftermarket investments across the next several quarters.

Dynatronics Business Overview & Revenue Model

Company Description

Dynatronics Corporation, a medical device company, designs, manufactures, and sells physical therapy, rehabilitation, orthopedics, pain management, and athletic training products in the United States. Its orthopedic soft bracing products include cervical collars, shoulder immobilizers, arm slings, wrist and elbow supports, abdominal and lumbosacral supports, maternity supports, knee immobilizers and supports, ankle walkers and supports, plantar fasciitis splints, and cold therapy products. The company provides therapeutic modality devices comprising electrotherapy, ultrasound, phototherapy, therapeutic lasers, shortwave diathermy, radial pulse therapy, hot and cold therapy, compression therapy, and electrodes. It also offers power and manually operated treatment tables, mat platforms, work tables, parallel bars, training stairs, weight racks, treadmills, and other related equipment. In addition, the company provides clinical supplies, including exercise bands and tubings, lotions and gels, orthopedic bracings, paper products, and other related supplies. It markets its products under the Bird & Cronin, Solaris, Hausmann, Physician's Choice, and PROTEAM brands. The company sells its products to orthopedists, physical therapists, chiropractors, athletic trainers, sports medicine practitioners, clinics, and hospitals, as well as online. It also exports its products to approximately 30 countries. Dynatronics Corporation was founded in 1979 and is headquartered in Eagan, Minnesota.

How the Company Makes Money

Dynatronics’ revenue has historically been generated primarily through the sale of physical medicine and rehabilitation products to healthcare providers and distributors. Key revenue streams have included (1) product sales of therapeutic modality equipment (e.g., electrotherapy, ultrasound, traction) and related rehabilitation devices, and (2) sales of consumables and accessories used with those devices (e.g., electrodes and other supplies), which can provide repeat purchasing tied to installed equipment. Revenue is recognized when products are sold and delivered through direct sales channels and/or distribution partners. Specific, current breakdowns by product line, customer segment, or major partnerships are null.

Dynatronics Financial Statement Overview

Summary

Financial statements indicate material weakness: declining revenue (TTM growth -2.11%), negative profitability (negative net and EBIT margins), high leverage (debt-to-equity 2.26), and weak cash generation with negative free cash flow growth and liquidity pressure.

Income Statement

Dynatronics has experienced declining revenue over the past few years, with a negative revenue growth rate of -2.11% in the TTM. The company is facing significant profitability challenges, as evidenced by negative net profit margins and EBIT margins. The gross profit margin has also decreased slightly over time, indicating pressure on cost management.

Balance Sheet

The balance sheet shows a high debt-to-equity ratio of 2.26 in the TTM, indicating significant leverage and potential financial risk. Return on equity is negative, reflecting ongoing losses. The equity ratio has decreased, suggesting a weakening financial position.

Cash Flow

Cash flow analysis reveals a concerning trend with negative free cash flow growth and low operating cash flow coverage ratio. The free cash flow to net income ratio is positive, but overall cash generation remains weak, highlighting liquidity challenges.

Breakdown	TTM	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	26.81M	27.39M	32.53M	40.61M	44.34M	47.80M
Gross Profit	5.76M	6.01M	7.63M	10.15M	10.67M	12.89M
EBITDA	-9.31M	-9.37M	-976.01K	-3.50M	-2.42M	3.81M
Net Income	-10.74M	-10.90M	-2.70M	-5.66M	-4.73M	1.21M
Balance Sheet
Total Assets	15.00M	15.44M	25.94M	30.06M	35.43M	39.14M
Cash, Cash Equivalents and Short-Term Investments	761.75K	326.34K	483.92K	398.80K	550.11K	6.10M
Total Debt	6.90M	6.63M	6.69M	5.65M	3.84M	5.08M
Total Liabilities	11.94M	12.18M	11.78M	13.21M	13.73M	13.63M
Stockholders Equity	3.06M	3.26M	14.16M	16.86M	21.70M	25.51M
Cash Flow
Free Cash Flow	75.88K	270.13K	-1.85M	185.15K	-5.20M	236.13K
Operating Cash Flow	106.62K	300.58K	-1.61M	372.00K	-4.88M	383.00K
Investing Cash Flow	-30.74K	-30.45K	-243.29K	-187.00K	-319.00K	1.53M
Financing Cash Flow	407.43K	-427.71K	1.84M	-332.71K	-350.00K	2.02M

Dynatronics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.04
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DYNTQ, the sentiment is Negative. The current price of 0.04 is above the 20-day moving average (MA) of 0.02, above the 50-day MA of 0.04, and below the 200-day MA of 0.07, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 27.37 is Positive, neither overbought nor oversold. The STOCH value of <0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DYNTQ.

Dynatronics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NUWE	43 Neutral	$2.40M	-0.69	-6046.59%	―	-8.93%	97.80%
VTAK	42 Neutral	$2.17M	-3.70	-173.74%	―	82.96%	82.04%
BJDX	42 Neutral	$1.80M	-0.18	-145.52%	―	―	97.70%
DYNTQ	40 Underperform	$107.53K	-1.05	-125.14%	―	-12.89%	-64.68%
DHAI	37 Underperform	$419.00	-0.95	―	―	―	―